CurrentCardio
Get Weekly

General medical journalCurrentCardio coverage

Nature Medicine

What CurrentCardio has captured from this journal. The coverage figures describe CurrentCardio's coverage, not the journal's output. Figures as of 13 October 2026.

Recent
6 Briefs
past 90 days
Archive
80 Briefs
research published Apr 2023 – Sep 2026
Editorial
–
no Weekly issue published yet
Impact Factor
52.5
2025 · Journal Citation Reports

Topics

Evidence types

Shares are of the 80 Briefs CurrentCardio has covered from Nat Med, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from Nature Medicine

All coverage, newest first

  1. Nat Med

    Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

    Randomised controlled trialHeart failure

  2. Nat Med

    Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium

    Meta-analysis

  3. Nat Med

    Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial

    Secondary analysisHeart failure

  4. Nat Med

    Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial

    Randomised controlled trialCoronary & ACS

  5. Nat Med

    Recombinant shingles vaccination and the risk of cardiovascular events

    Cohort studyCardio-oncology & other

  6. Nat Med

    Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial

    Randomised controlled trialHeart failure

  7. Nat Med

    Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial

    Randomised controlled trialHeart failure

  8. Nat Med

    A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials

    Meta-analysisHypertension

  9. Nat Med

    Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial

    Research articleHeart failure

  10. Nat Med

    Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

    Secondary analysisHeart failure

  11. Nat Med

    Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial

    Randomised controlled trialHeart failure

  12. Nat Med

    The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial

    Randomised controlled trialHeart failure

  13. Nat Med

    Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

    Diagnostic or prognostic studyPrevention & lipids

  14. Nat Med

    The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial

    Randomised controlled trialHeart failure

  15. Nat Med

    Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990–2023: a Global Burden of Disease study

    Research articlePrevention & lipids

  16. Nat Med

    DASH-patterned groceries and effects on blood pressure in adults treated for hypertension: the GoFreshRx randomized trial

    Randomised controlled trialHypertension

  17. Nat Med

    Remote monitoring of heart failure exacerbations using a smartwatch

    Cohort studyHeart failure

  18. Nat Med

    Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

    Randomised controlled trialPrevention & lipids

  19. Nat Med

    Lay community health worker-led care with mobile decision support for uncontrolled hypertension: a cluster-randomized trial

    Randomised controlled trialHypertension

  20. Nat Med

    Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study

    Secondary analysisArrhythmias & EP

  21. Nat Med

    A large language model for complex cardiology care

    Randomised controlled trialHeart failure

  22. Nat Med

    Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial

    Secondary analysisCoronary & ACS

  23. Nat Med

    The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension

    Diagnostic or prognostic studyPulmonary vascular & VTE

  24. Nat Med

    Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial

    Randomised controlled trialCoronary & ACS

  25. Nat Med

    Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial

    Randomised controlled trialArrhythmias & EP

  26. Nat Med

    Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial

    Randomised controlled trialCoronary & ACS

  27. Nat Med

    Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

    Cohort studyCardiometabolic & kidney

  28. Nat Med

    Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction

    Randomised controlled trialHeart failure

  29. Nat Med

    Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial

    Randomised controlled trialCoronary & ACS

  30. Nat Med

    Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial

    Randomised controlled trialHeart failure

  31. Nat Med

    AI-based diagnosis of acute aortic syndrome from noncontrast CT

    Diagnostic or prognostic studyAortic & peripheral

  32. Nat Med

    Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial

    Secondary analysisHeart failure

  33. Nat Med

    Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial

    Randomised controlled trialHypertension

  34. Nat Med

    Performance of the American Heart Association’s PREVENT risk score for cardiovascular risk prediction in a multiethnic population

    Cohort studyPrevention & lipids

  35. Nat Med

    Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEEER-AF cluster-randomized clinical trial

    Randomised controlled trialArrhythmias & EP

  36. Nat Med

    Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial

    Randomised controlled trialArrhythmias & EP

  37. Nat Med

    Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial

    Randomised controlled trialHypertension

  38. Nat Med

    Meta-prediction of coronary artery disease risk

    Diagnostic or prognostic studyCoronary & ACS

  39. Nat Med

    Implementation of a national AI technology program on cardiovascular outcomes and the health system

    Cohort studyCoronary & ACS

  40. Nat Med

    Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency

    Meta-analysisHeart failure

All 80 Briefs in ExploreShowing the 40 most recently published